Abstract
Background and aim of the study
The Valiant NavionTM stent graft system
is a third-generation low profile thoracic endograft designed for
thoracic endovascular aortic repair. In this population analysis, we
report on the first Asian all-comers experience and outcomes who
underwent thoracic endovascular aortic repair with the use of this new
stent graft system.
Methods
Between May 2019 and October 2020, 21
patients with different aortic pathologies were prospectively recruited
and retrospectively analyzed. Important clinical and device-related
outcomes were evaluated. The endpoints included short-term survival,
technical success, access failures, major vascular and clinical
complications, endoleaks, and hospital stay.
Results
The commonest
indication of stenting was penetrating aortic ulcers (28.6%) and 6
(28.6%) patients had emergency stenting performed for aortic
transection or rupture. 30 days of survival post-procedure was recorded
and complete. There were no major vascular complications. Deployment
accuracy was 100%, and the technical success rate was 94.7% (18/19)
with 1 patient having a type 2 endoleak on follow-up imaging. No
neurological complications were noted. The mean operative time was 95
+/- 73.6 mins and the mean fluoroscopy time was 16.2 +/- 10.8 mins. Mean
hospital stay for elective zone 2, 3 and 4 stenting was 5.3 +/- 3.8
days, and only 1 patient post zone 1 TEVAR required a brief (0.5 days)
ICU stay. All procedures were performed via the percutaneous
transfemoral route with 100% success in percutaneous closure.
Conclusion
This first reported Asian case series demonstrated
versatility, safety, and efficacy of the Valiant NavionTM stent in Asian
patients with different aortic pathologies
, 
